Suppr超能文献

伽玛刀放射外科治疗垂体腺瘤时垂体出血的发生率、危险因素及预后

Pituitary hemorrhage in pituitary adenomas treated with gamma knife radiosurgery: incidence, risk factors and prognosis.

作者信息

Fu Junyi, Li Yanli, Wu Lisha, Yang Xin, Quan Tingting, Li Xi, Zeng Jiamin, Deng Yinhui, Yu Jinxiu

机构信息

Department of Neurology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China. 510260.

Department of Endocrinology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China. 510260.

出版信息

J Cancer. 2021 Jan 1;12(5):1365-1372. doi: 10.7150/jca.52349. eCollection 2021.

Abstract

: The aims of this study were to investigate the incidence, risk factors and prognosis of pituitary hemorrhage in pituitary adenomas treated with gamma knife radiosurgery (GKRS). Between December 1993 and December 2016, 751 consecutive pituitary adenoma patients treated with GKRS were retrospectively reviewed in a single center. There were 271 male (36.1%) and 480 female (63.9%) patients with a median age of 38.5 (range, 7.2-84.0) years. The number of nonfunctioning pituitary adenomas (NFPAs) and functioning pituitary adenomas were 369 (49.1%) and 382 (50.9%) respectively. The median follow-up time was 61.1 (range, 12.1-304.4) months. In this study, 88 patients (11.7%) were diagnosed with pituitary hemorrhage before GKRS, 55 patients (7.3%) developed new or worsened pituitary hemorrhage after GKRS (excluding 3 patients with new or worsened pituitary hemorrhage due to tumor regrowth). The median time to new or worsened pituitary hemorrhage after GKRS was 18.9 (range 3.1-70.7) months. Overall, 128 patients (17.0%) were diagnosed with pituitary hemorrhage in the entire series. After adjustment with logistic regression, nonfunctioning pituitary adenomas (NFPAs) (odds ratio [OR]=2.121, 95% confidence interval [CI]=1.195-3.763, =0.010) and suprasellar extension (OR=2.470, 95% CI=1.361-4.482, =0.003) were associated with pituitary hemorrhage before GKRS. NFPA (OR=3.271, 95% CI=1.278-8.373, =0.013) was associated with new or worsened pituitary hemorrhage after GKRS. Five patients received surgical resection for new or worsened pituitary hemorrhage were considered as GKRS treatment failure. Two patients with new hypopituitarism were considered to be owed to new or worsened pituitary hemorrhage after GKRS. New or worsened pituitary hemorrhage after GKRS was not an uncommon phenomenon. NFPA was an independent risk factor of new or worsened pituitary hemorrhage after GKRS. New or worsened pituitary hemorrhage after GKRS could lead to GKRS treatment failure. GKRS might be a precipitating factor of pituitary hemorrhage.

摘要

本研究的目的是调查伽玛刀放射外科治疗(GKRS)垂体腺瘤时垂体出血的发生率、危险因素及预后情况。1993年12月至2016年12月期间,在单中心对751例连续接受GKRS治疗的垂体腺瘤患者进行回顾性分析。其中男性271例(36.1%),女性480例(63.9%),中位年龄38.5岁(范围7.2 - 84.0岁)。无功能垂体腺瘤(NFPA)和有功能垂体腺瘤的数量分别为369例(49.1%)和382例(50.9%)。中位随访时间为61.1个月(范围12.1 - 304.4个月)。本研究中,88例患者(11.7%)在GKRS治疗前被诊断为垂体出血,55例患者(7.3%)在GKRS治疗后出现新的或加重的垂体出血(不包括3例因肿瘤复发导致新的或加重的垂体出血患者)。GKRS治疗后出现新的或加重的垂体出血的中位时间为18.9个月(范围3.1 - 70.7个月)。总体而言,整个队列中有128例患者(17.0%)被诊断为垂体出血。经逻辑回归调整后,无功能垂体腺瘤(NFPA)(比值比[OR]=2.121,95%置信区间[CI]=1.195 - 3.763,P = 0.010)和鞍上扩展(OR=2.470,95% CI=1.361 - 4.482,P = 0.003)与GKRS治疗前的垂体出血相关。NFPA(OR=3.271,95% CI=1.278 - 8.373,P = 0.013)与GKRS治疗后新的或加重的垂体出血相关。5例因新的或加重垂体出血接受手术切除的患者被视为GKRS治疗失败。2例出现新的垂体功能减退的患者被认为是由于GKRS治疗后新的或加重的垂体出血所致。GKRS治疗后新的或加重的垂体出血并非罕见现象。NFPA是GKRS治疗后新的或加重垂体出血的独立危险因素。GKRS治疗后新的或加重的垂体出血可导致GKRS治疗失败。GKRS可能是垂体出血的促发因素。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验